Amicus Therapeutics

Amicus Therapeutics Announces European Commission Approval of Galafold® (migalastat) for Adolescents with Fabry Disease

PHILADELPHIA, PA — Amicus Therapeutics (Nasdaq: FOLD) recently announced the European Commission has approved Galafold® (migalastat) for use in adolescents aged 12 to <16 years weighing ≥ 45 kg with …

Amicus Therapeutics Announces European Commission Approval of Galafold® (migalastat) for Adolescents with Fabry Disease Read More